ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer-Reference-Cited by-同舟云学术

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Published:2020-03 Issue: Volume:473 Page:156-163
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Barok Mark,Le Joncour Vadim,Martins Ana,Isola Jorma,Salmikangas Marko,Laakkonen Pirjo,Joensuu Heikki

Funder

Academy of Finland

Cancer Society of Finland

Sigrid Jusélius Foundation

Jane and Aatos Erkko Foundation

Finnish Cancer Organizations

K. Albin Johansson foundation

Helsinki University Research Grants

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

3. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann. Oncol.,2008

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer;Journal of Experimental & Clinical Cancer Research;2024-08-21

2. HER-2 positive gastric cancer: Current targeted treatments;International Journal of Biological Macromolecules;2024-08

3. The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases;Pharmaceutics;2024-07-02

4. The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity;ChemMedChem;2024-07-02

5. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer;Cancer Drug Resistance;2024-06-03